Stocktoria

BICYCLE THERAPEUTICS PLC BCYC

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-05-23 · LEI

BICYCLE THERAPEUTICS PLC financials (annual)

Revenue
$7.1M $13.8M $10.4M $11.7M $14.5M $27.0M $35.3M $72.6M 20182019202020212022202320242025
Net income
-$21.8M -$30.6M -$51.0M -$66.8M -$112.7M -$180.7M -$169.0M -$219.0M 20182019202020212022202320242025
Free cash flow
-$27.3M -$30.2M -$19.0M -$16.8M -$105.1M -$63.6M -$166.0M -$252.0M 20182019202020212022202320242025

Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue$72.6M$35.3M$27.0M$14.5M$11.7M$10.4M$13.8M$7.1M
R&D expense$240.3M$173.0M$156.5M$81.6M$44.9M$33.1M$25.5M$20.8M
Operating income-$247.1M-$209.9M-$189.9M-$116.7M-$65.6M-$52.0M-$26.3M-$21.7M
Interest expense——$3.3M$3.3M$3.0M$457,000——
Income tax$152,000-$4.8M$1.5M-$1.5M-$1.7M-$724,000-$254,000-$396,000
Net income-$219.0M-$169.0M-$180.7M-$112.7M-$66.8M-$51.0M-$30.6M-$21.8M
EPS (diluted)$-3.16$-2.90$-5.08$-3.80$-2.67$-2.66$-2.77—
Operating cash flow-$249.7M-$164.7M-$60.6M-$86.1M-$14.8M-$17.8M-$28.6M-$26.1M
Free cash flow-$252.0M-$166.0M-$63.6M-$105.1M-$16.8M-$19.0M-$30.2M-$27.3M
Cash & equivalents$628.1M$879.5M$526.4M$339.2M$438.7M$0$0$0
Total assets$717.6M$956.9M$595.3M$410.6M$479.8M$161.2M$110.2M$81.6M
Total liabilities$107.6M$163.8M$224.4M$139.8M$133.5M$65.7M$17.0M$29.3M
Shareholders' equity$610.0M$793.1M$370.9M$270.8M$346.3M$95.5M$93.2M-$69.8M

Growth · year-over-year · Revenue CAGR 39.3%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue growth+105.8%+30.8%+86.5%+23.6%+12.6%-24.7%+93.4%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.